Klotho Neurosciences (KLTO) Stock Price, News & Analysis

Company Overview

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Key Stats

• Today's Range: $0.43 to $0.47
• 50-Day Range: $0.28 to $0.70
• 52-Week Range: $0.26 to $13.10
• Volume: 85,832 shs
• Average Volume: 2.08 million shs
• Market Capitalization: $9.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KLTO Stock Analysis - Frequently Asked Questions

How have KLTO shares performed this year?

Klotho Neurosciences' stock was trading at $0.4850 at the start of the year. Since then, KLTO shares have decreased by 9.1% and is now trading at $0.4410.
View the best growth stocks for 2025 here.

How do I buy shares of Klotho Neurosciences?

Shares of KLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 1/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KLTO
• Previous Symbol: NASDAQ:KLTO
• CUSIP: N/A
• CIK: 1907223
• Web: www.klothoneuro.com
• Phone: (833) 931-6330
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -25.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.16
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.43 per share
• Price / Cash Flow: 1.03
• Book Value: ($2.16) per share
• Price / Book: -0.20

Miscellaneous

• Outstanding Shares: 21,260,000
• Free Float: 20,839,000
• Market Cap: $9.38 million
• Optionable: N/A
• Beta: N/A